Puma Biotechnology Inc (NASDAQ:PBYI) management will conduct a conference call for 5th November 2020 at 4:30 PM Eastern Time to discuss financial results and companys performance for 3Q20.
The conference call will also be available live on the website www.pumabiotechnology.com
Earnings Expectation
Puma Biotechnology Inc is expected to report third quarter earnings results, after market close, on Thursday 5th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.39 per share from revenue of $ 53.05 million. Looking ahead, the full year loss are expected at $ 1.04 per share on the revenues of $ 232.99 million.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4.